Nature Medicine Archives - PharmaDeviceNews

Representative image: Gastric cancer imaging and biomarker analysis illustrate ALX Oncology’s evorpacept results in HER2-positive, CD47-high tumors from the ASPEN-06 study.

Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus

by Soujanya Ravi
September 28, 2026
0 Comments

ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.

Vero Bioscience is combining Stanford University’s proteomic organ-aging and Cell Clock technologies to develop OrganAge, a blood-based platform designed to assess biological aging across organs and cell types as the company moves toward broader consumer availability in 2027. Representative image.

Medical Devices & Diagnostics

Can one blood test reveal which cells are aging fastest? Vero brings Stanford Cell Clock into OrganAge

by Pallavi Madhiraju
August 19, 2026
0 Comments

Vero adds Stanford Cell Clock technology to OrganAge ahead of a 2027 rollout, while clinical validation remains the key commercial test.

Tempus AI’s PRISM2 pathology foundation model showed strong retrospective performance across cancer detection, biomarker prediction and survival analysis, strengthening interest in general-purpose artificial intelligence for digital pathology. Representative image.

Medical Devices & Diagnostics

Tempus AI trained PRISM2 on 2.3m pathology slides. Can one model detect cancer and predict what happens next?

by Pallavi Madhiraju
August 9, 2026
0 Comments

Tempus AI’s PRISM2 foundation model matched or exceeded specialised pathology products across several retrospective cancer-detection tests while also supporting biomarker and survival predictions. The results strengthen the case for general-purpose pathology artificial intelligence, but PRISM2 is not yet an FDA-authorised diagnostic device.